Clinical trial
A Phase I/II Study of 153 Sm EDTMP (Quadramet™) and PS-341 (Velcade®) in Patients With Relapsed or Refractory Multiple Myeloma
NCT00478075 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study of 153 Sm EDTMP (Quadramet™) and PS-341 (Velcade®) in Patients With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 30, 2005
- Completion date
- June 30, 2009
- Enrollment
- 50 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
multiple myeloma and plasma cell neoplasm